Skip to content

About Us
Our Approach
Pipeline
- Overview
- Publications
Clinical Trials
Investors
Contact

About Us
Our Approach
Pipeline
- Overview
- Publications
Clinical Trials
Investors
Contact

PRESS RELEASES

Choose Year
Search Press Releases

Found 214 Results

May 31, 2017

Minerva Announces Amended Agreement for MIN-202 in Insomnia

May 30, 2017

Minerva Neurosciences to Present at Jefferies 2017 Healthcare Conference on June 6, 2017

May 15, 2017

Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA

May 15, 2017

Minerva Provides Update on Phase 3 Design and Development Strategy for MIN-101

May 4, 2017

Minerva Neurosciences Reports First Quarter 2017 Financial Results and Business Updates

April 27, 2017

Minerva Neurosciences to Report First Quarter 2017 Financial Results and Business Updates on May 4, 2017

March 21, 2017

Minerva Neurosciences Announces Recent Exercise of Warrants by Institutional Stockholders and Open Market Purchase of Common Stock by Chairman of Its Board of Directors

March 13, 2017

Minerva Neurosciences Reports Fiscal 2016 Fourth Quarter and Year End Financial Results and Business Updates

March 6, 2017

Minerva Neurosciences to Report Fiscal 2016 Fourth Quarter and Year End Financial Results and Business Updates on March 13, 2017

February 28, 2017

Minerva Neurosciences to Present at Cowen and Company 37th Annual Health Care Conference on March 7, 2017

«...13 141516 17...»

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Minerva Neurosciences, Inc.
1500 District Avenue
Burlington, MA 01803

Company

About Us
Leadership
Board of Directors
Contact

Science

Our Approach
Pipeline
Publications
Clinical Trials

Investors

Investors Overview
News
Events
SEC Filings
Stock Information
Corporate Governance
FAQs

© 2026 Minerva Neurosciences, Inc.

Privacy Policy
Terms of Use
Accessibility Statement
Cookie Policy

Scroll to Top